Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease

Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease Abstract. In previous studies, we have found Hemate P (Behring) to be the only commercial virus‐inactivated high‐purity factor VIII concentrate that contains native von Willebrand factor. In the present study, Hemate P was given to 7 patients with the severe recessive form of von Willebrand's disease, to 2 patients with type Ia, to 1 patient with type IIB, and to 1 patient with type IIC von Willebrand's disease. A correction of the hemostatic defect was seen in all patients. Satisfactory hemostasis was also obtained in clinical situations, 1 patient undergoing major surgery and another being delivered, both without undue loss of blood. We conclude that Hemate P is an efficacious and safe product for use in cases of von Willebrand's disease when pharmacological correction of the hemostatic defect is not possible. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Vox Sanguinis Wiley

Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease

Vox Sanguinis , Volume 56 (4) – May 1, 1989

Loading next page...
 
/lp/wiley/use-of-a-high-purity-factor-viii-concentrate-hemate-p-in-von-93BARRXjHx

References (26)

Publisher
Wiley
Copyright
© 1989 S. Karger AG, Basel
ISSN
0042-9007
eISSN
1423-0410
DOI
10.1111/j.1423-0410.1989.tb02031.x
Publisher site
See Article on Publisher Site

Abstract

Abstract. In previous studies, we have found Hemate P (Behring) to be the only commercial virus‐inactivated high‐purity factor VIII concentrate that contains native von Willebrand factor. In the present study, Hemate P was given to 7 patients with the severe recessive form of von Willebrand's disease, to 2 patients with type Ia, to 1 patient with type IIB, and to 1 patient with type IIC von Willebrand's disease. A correction of the hemostatic defect was seen in all patients. Satisfactory hemostasis was also obtained in clinical situations, 1 patient undergoing major surgery and another being delivered, both without undue loss of blood. We conclude that Hemate P is an efficacious and safe product for use in cases of von Willebrand's disease when pharmacological correction of the hemostatic defect is not possible.

Journal

Vox SanguinisWiley

Published: May 1, 1989

There are no references for this article.